You searched for "AMD"
OCT Angiography in Retinal and Macular Diseases
OCT angiography (OCT-A) is based on the concept that in a static eye, the only moving structure in the fundus of the eye is blood flowing through the vessels. This book explains how the technique allows a depth-resolved analysis and...Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting
The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...Ophthalmology (third edition)
1 December 2018
| Hasan A Usmani
|
Ophthalmology
If you are an ophthalmologist who enjoys books with coloured pictures, you’re no lone wolf. The third edition of Lang’s Ophthalmology will definitely pique your primal ophthalmologist instincts. You will be drawn to its soft-bound yet sturdy looking exterior. Flicking...
The effects of anti-VEGF therapy for NvAMD on retinal vasculature
4 August 2021
| Su Young
|
Retina / Uvea / Vitreous
|
aflibercept, foveal avascular zone, neovascular age-related macular degeneration, ranibizumab, retinal vessel density
This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...
Exploring the potential of neurodegenerative disease screening within age-related eye disease research
3 August 2023
| Lauren R Hepworth
|
Neuro-Ophthalmology
The authors recruited healthy controls aged between 60 and 75-years-old, previously enrolled into a registry as patients following cataract surgery without age-related macular degeneration (AMD). Exclusion criteria included dense cataract, retinal disease, ocular inflammatory disease, moderate glaucoma, optic neuropathy, cancer,...
Macular atrophy with aflibercept
1 October 2018
| Saruban Pasu
|
Retina / Uvea / Vitreous
The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...
Systemic pharmacology of intravitreal anti-VEGF
1 April 2018
| Saruban Pasu
|
Retina / Uvea / Vitreous
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
Data update for leading causes of CVI in England and Wales
In this article the authors present an epidemiological update, based on certifiable visual impairment (CVI) registration for figures for sight impairment (SI) in England and Wales from the last report of 2007-2008 to the current data for April 2012 to...Transforming lives in Bolivia: A successful partnership with the Andean Medical Mission and Surgitrac
23 July 2024
|
Company Profiles, Global Health
Using consumables donated by Surgitrac Instruments, the Andean Medical Mission (AMM) has just returned from a transformative one-month trip to northern Bolivia.
Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice
1 February 2015
| Pearse A Keane (Prof), Adnan Tufail
|
Retina / Uvea / Vitreous
The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...
Advances and developments in medical retina
The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...Eye Capacity: clinical need should drive ophthalmic service provision
1 February 2014
| Rod McNeil
Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...